What is the recommended dose of Lamisil (terbinafine) for mild fungal infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Terbinafine (Lamisil) Dosing for Mild Fungal Infections

For mild fungal infections, terbinafine (Lamisil) is recommended at a dose of 250 mg once daily, with duration varying by infection site: 6 weeks for fingernail infections and 12 weeks for toenail infections. 1

Dosing Recommendations by Infection Type

Onychomycosis (Nail Infections)

  • 250 mg oral terbinafine once daily for 6 weeks for fingernail infections 2, 1
  • 250 mg oral terbinafine once daily for 12 weeks for toenail infections 2, 1
  • For children weighing 20-40 kg: 125 mg/day; for children <20 kg: 62.5 mg/day; for children >40 kg: adult dose of 250 mg 3

Cutaneous Dermatophyte Infections

  • 250 mg oral terbinafine once daily for tinea corporis/cruris (ringworm) for 2-4 weeks 4
  • 250 mg oral terbinafine once daily for tinea pedis (athlete's foot) for 2-6 weeks 4
  • For topical treatment of mild superficial infections: apply terbinafine 1% cream once or twice daily for up to 2 weeks 4

Efficacy and Mechanism of Action

  • Terbinafine is an allylamine antifungal with fungicidal activity against dermatophytes 2
  • It inhibits squalene epoxidase in the ergosterol biosynthesis pathway, causing both ergosterol depletion (fungistatic effect) and toxic squalene accumulation (fungicidal effect) 5
  • Terbinafine has a very low minimum inhibitory concentration (MIC) of approximately 0.004 μg/mL against dermatophytes 2
  • It is more effective than itraconazole and griseofulvin for dermatophyte infections, with mycological cure rates generally >80% 4, 5

Clinical Considerations

  • Terbinafine persists in the nail for a considerable period after elimination from plasma, allowing for shorter treatment durations compared to other antifungals 2
  • For mild fungal infections, terbinafine is generally well-tolerated with minimal side effects 4
  • Common adverse effects include headache, diarrhea, rash, dyspepsia, liver enzyme abnormalities, and taste disturbance 1
  • Mycological cure rates typically improve after treatment cessation due to terbinafine's fungicidal mechanism and residual effect in tissue 4

Important Precautions and Monitoring

  • Liver function should be monitored as liver failure has been reported in rare cases 1
  • Discontinue treatment if liver injury, taste disturbance, or smell disturbance develops 1
  • Terbinafine is contraindicated in patients with a history of allergic reaction to the drug 1
  • Drug interactions are possible as terbinafine inhibits CYP450 2D6 isozyme, affecting metabolism of certain medications 1

Special Populations

  • Terbinafine is not recommended during pregnancy 2
  • Manufacturers caution against men fathering a child for 6 months after therapy 2
  • For children with tinea capitis, terbinafine has shown high efficacy (93% cure rate) with a 4-week treatment duration 3

Terbinafine's fungicidal mechanism of action makes it particularly effective for dermatophyte infections, with higher cure rates and lower relapse rates compared to azole antifungals like itraconazole 2, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Overview of the use of terbinafine (Lamisil) in children.

The British journal of dermatology, 1995

Research

Terbinafine: a review of its use in onychomycosis in adults.

American journal of clinical dermatology, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.